الجمعة 12 جمادى الأولى 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
تحقق من أن الموقع يستخدم بروتوكول HTTPS
مسجل لدى هيئة الحكومة الرقمية برقم :
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease | Celgene | Ongoing | Ozanimod HCl | 3 | RPC01-3203 | King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh) |
| A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer | NRG Oncology King Faisal Specialist Hospital & Research Center | Ongoing | CISPLATIN (CISPLATYL ) | 2 | NRG-HN002 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Study of Aflibercept in Uveitic Macular EDema (SAUD study) | King Khalid Eye Specialist Hospital | Rejected | Aflibercept | 3 | 18176/ | King Khaled Eye Specialist Hospital (Riyadh) |
| A Phase Ib study to determine the safety and immunogenicity of the candidate Middle East Res-piratory Syndrome Coronavirus (MERS-CoV) vaccine ChAdOx1 MERS in healthy adult Middle Eastern volunteers | KAIMRC | Ongoing | vaccine ChAdOx1 MERS | 1 | CT18/004/R | King Abdulaziz Medical City NG (Riyadh) |
| Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia | Hikma | Rejected | Dasatinib | 2 | LPI-JOR-LEB-KSA-TUN- | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease. | Celgene | Ongoing | Ozanimod HCl | 3 | RPC01-3201 | King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh) |
| A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease | Celgene | Ongoing | Ozanimod HCl | 3 | RPC01-3204 | King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh) |
| A multi-center open-label parallel group randomized controlled trial to compareiGlarLixi versus premixed insulin in patients with type 2 diabetes who have failedto achieve glycemic control with basal insulin and oral antidiabetic agents | Sanofi | Ongoing | Insulin glargine/Lixisenatide | 3b | LPS15017 | King Fahad Medical City (Riyadh) |
| A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease | Janssen-Cilag International NV | Ongoing | Guselkumab | 2 | CNTO1959CRD3001 | King Abdullah Medical City (Makkah), King Abdulaziz Medical City NG (Riyadh) |
| A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease (HESTIA3) | Astrazeneca | Ongoing | Ticagrelor | 3 | D5136C00009 | King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh) |
تاريخ آخر تحديث: 06/10/2026 بتمام الساعة 08:14 صباحا بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.